Details of the Drug

General Information of Drug (ID: DMV1J21)

Drug Name
AAV-hTERT
Indication
Disease Entry ICD 11 Status REF
Aging MG2A Phase 1 [1]
Alzheimer disease 8A20 Phase 1 [1]
Critical limb ischemia BD4Y Phase 1 [2]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
DI9X5U
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Telomerase reverse transcriptase (TERT) TTUJFD0 TERT_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Aging
ICD Disease Classification MG2A
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Telomerase reverse transcriptase (TERT) DTT TERT 8.59E-10 -0.08 -0.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04133649) Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for the Treatment of Aging: AAV- hTERT. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04110964) Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Critical Limb Ischemia: AAV- hTERT. U.S.National Institutes of Health.